Absci Corporation

Good day and thank you for standing by. Welcome to the ABPSI second quarter business update. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Alex Khan, Corporate Vice President and Investor Relations. Please go ahead.

Thank you. Earlier today, Abcide released financial and operating results for the quarter ended June 30, 2026. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investors at Abcide.com. An archived webcast of this call will be available for replay on Abcide's Investor Relations website at investors.abcide.com for at least 90 days after this call. Joining me today are Sean McClain, Abcide's founder and CEO, Zach Jonasson, Chief Financial Officer and Chief Business Officer, and Ranti Somaratne, Chief Medical Officer, Head of R&D. Before we begin, I'd like to remind you the manager will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. They should not place undue reliance on forward-looking statements. These include statements regarding the development and clinical progress of our pipeline programs, including ABS-201, the design, enrollment, conduct, and timelines of our ongoing Phase 1-2A headline trial of ABS-201, the anticipated timing of an interim proof-of-concept data readout for ABS-201 in the second half of 2026, and full proof-of-concept data in early 2027, The potential advancement of ABS-201 into Phase 3 development The anticipated initiation of a Phase 2 clinical trial of ABS-21 for endometriosis in the fourth quarter of 2026 and potential proof-of-concept readout in the second half of 2027 Anticipated characteristics and product profile of ABS-21 as a drug product Our target product profile and its attributes The potential for an expedited development pathway, including the possibility of advancing directly from Phase 1 to A into Phase 3 Our planned engagement with the FDA regarding development strategy Our partnership with Eli Lilly including anticipated benefits thereof and Eli Lilly's participation on our Endometriosis Advisory Board. The capabilities anticipated benefits are about platform technology such as Atlas and potential market opportunity and commercial prospects for ABS 201. Certain statements may also include projections regarding potential market opportunity. These estimates are based on various assumptions, including potential regulatory approval, final approved label, and the evolving competitive landscape, any of which could cause our actual addressable market to differ materially from these projections. In addition, certain research findings discussed today reflect participant responses to a hypothetical product profile and do not represent clinical results for ABUS-201. Additional information regarding the risks and uncertainties that could affect our forward-looking statements is set forth in the press release to ABSEI issued today, our most recent annual report in Form 10-K, and subsequent documents and reports filed by ABSEI for design with the SEC. Except as required by law, ABSEI disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, either because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, August 11, 2026. With that, I'll turn the call over to Sean.

Thanks, Alex. Good afternoon, everyone. Thanks for joining us today. Abcide continues to execute and I'll walk you through recent highlights, including key progress on ongoing headline trial, our new partnership with Eli Willey, and our $100 million financing completed at the end of June. Starting with headlines. In June, we released positive interim phase one data. The data suggests the study drug was well tolerated with favorable safety and tolerability. And based on interim PK data, ABS 201's Half-Life supports the potential for just two to three injections over six months. This is exactly why we built our AI platform to design molecules that meet our target product profile we set out from day one. You've heard us say the prolactin mechanism is underappreciated. Everything we've learned has only strengthened that conviction, and we believe targeting the prolactin receptor has the potential across numerous diseases. And we are also excited to have a partner who shares in that vision. As you saw in June, we announced that Eli Lilly made a $40 million strategic investment in AMSI. Our partnership with Eli Lilly is tailored around the clinical development strategy for AVS201. And as a part of this collaboration, we are happy to be welcoming a representative from Lilly onto our Endometriosis Advisory Board. Zach will provide more details of this partnership later in the call. In addition to Lilly, We've seen elevated interest from the investment community in prolactin biology. In June, we completed $100 million financing, including the $40 million investment from Lilly, from a group of blue chip investors. We're grateful for this support, which enables the continued development of our existing programs, as well as future expansion of our pipeline. ADS-201's progress is a testament to the platform and the team that created it. Building on that leadership in de novo antibody design with origin, we've now extended the platform upstream with Atlas, Abcide's target to lead autonomous scientists. Atlas is an agentic discovery engine built to remove the bottleneck ahead of design, rapidly identifying and validating the right targets. Atlas integrates literature, to surface and triage novel target hypothesis. These flow directly into origin for epitope specific de novo design and then into our in-house wet lab for characterization and pathway validation. This process closes a hypothesis to molecule loop and turns discovery into a high throughput fail fast engine by having more shots on goal and better ones. We're already seeing this at work. Atlas has surfaced potential new indications for a prolactin receptor franchise and independently recovered genetic evidence linking this pathway to pattern hair loss and endometriosis. This is a powerful new tool that every drug hunter at AbSci can now leverage. We'll continue deploying this AI native platform to create therapeutics like ABS201 with the potential to change the treatment paradigm for patients. With that, I'll turn it over to Ronzi to walk through the ABS201 clinical program. Ronzi?